H.C. Wainwright Initiates Coverage on Karyopharm Therapeutics Inc(NASDAQ:KPTI). The shares have been rated Buy. The rating by H.C. Wainwright was issued on Aug 18, 2016.
In a different note, On Aug 30, 2016, Jefferies said it Upgrades its rating on Karyopharm Therapeutics Inc. In the research note, the firm Raises the price-target to $9.00 per share. The shares have been rated ‘Buy’ by the firm. Baird said it Initiates Coverage on Karyopharm Therapeutics Inc, according to a research note issued on Jun 28, 2016. The shares have been rated ‘Outperform’ by the firm. Raymond James said it Initiates Coverage on Karyopharm Therapeutics Inc, according to a research note issued on May 27, 2016. The shares have been rated ‘Outperform’ by the firm.
Karyopharm Therapeutics Inc (KPTI) made into the market gainers list on Mondays trading session with the shares advancing 2.89% or 0.2 points. Due to strong positive momentum, the stock ended at $7.12, which is also near the day’s high of $7.1612. The stock began the session at $6.97 and the volume stood at 83,342 shares. The 52-week high of the shares is $19.407 and the 52 week low is $4.83. The company has a current market capitalization of $256 M and it has 3,59,89,260 shares in outstanding.
Karyopharm Therapeutics Inc(KPTI) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $59.00K. Analysts had an estimated revenue of $40.00K. Earnings per share were $-0.84. Analysts had estimated an EPS of $-0.76.
Several Insider Transactions has been reported to the SEC. On Dec 10, 2015, Mansoor Raza Mirza (director) sold 15,000 shares at $15.01 per share price.Also, On Apr 8, 2015, Ran Frenkel (EVP, WW Development Operations) purchased 3,000 shares at $31.22 per share price.On Apr 6, 2015, Justin A Renz (CFO) purchased 5,000 shares at $29.71 per share price, according to the Form-4 filing with the securities and exchange commission.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibits the nuclear export protein XPO1. The Company is seeking the regulatory approval and commercialization of its lead drug candidate selinexor (KPT-330) as a single orally administered agent in cancer indications with unmet clinical need initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.